We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA announced that a collection of information entitled ''Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens That are Not Individually Identifiable,'' has been approved by the Office of Management and
Budget (OMB) under the Paperwork Reduction Act of 1995.
An independent panel commissioned last summer to review Guidant's handling of its failed heart devices said the company should form an external committee of experts to serve as advisers.
Bay State officials and biotech leaders are lobbying for a law that would permit small companies that are funded primarily by venture capitalists to compete for government research grants that help small businesses fine-tune new medical breakthroughs.
Positron Corporation today announced that the Company has recently received approval from Health Canada to use Positron's mPower PET scanner in oncology and cardiology clinical trials in Canada.
Ekos, a Bothell company that combines ultrasound and drugs to break up blood clots, announced $26 million in venture capital financing today to build its sales effort and reach for profitability.
Medical and financial information gathered on millions of Americans by Medicare, Medicaid and other government programs is vulnerable to thieves or pranksters because of inadequate computer security, federal investigators say.
At the 73rd Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) studies were presented about how these two factors aging and excess weight impact patient outcome after hip replacement, revision hip replacement and fracture-related surgical treatment.
As many Americans live longer and exercise more and many others become increasingly obese the number of artificial joints that will be needed to replace damaged knees will jump 673 percent by 2030 to 3.48 million a year, a new study said.
Keryx Biopharmaceuticals has entered into an agreement to acquire Accumin, a diagnostic for the measurement of intact urinary albumin from AusAm Biotechnologies.